Last Updated : April 10, 2024
Details
Generic Name:
clindamycin plus benzoyl peroxide and adapalene
Project Status:
Active
Therapeutic Area:
acne vulgaris
Manufacturer:
Bausch Health, Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0794-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Combination of clindamycin phosphate, adapalene and benzoyl peroxide indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Combination of clindamycin phosphate, adapalene and benzoyl peroxide indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | January 29, 2024 |
|---|---|
| Call for patient/clinician input closed | March 25, 2024 |
| Clarification: - Patient input submission received from Acne and Rosacea Society of Canada (ARSC) and Canadian Skin Patient Alliance (CSPA) | |
| Submission received | March 08, 2024 |
| Submission accepted | - |
| Clarification: - Submission was not accepted for review on 25 Mar 2024 | |
| Review initiated | March 27, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | June 12, 2024 |
| Deadline for sponsors comments | June 21, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | August 16, 2024 |
| Expert committee meeting (initial) | August 28, 2024 |
| Draft recommendation issued to sponsor | September 10, 2024 To September 12, 2024 |
| Draft recommendation posted for stakeholder feedback | September 19, 2024 |
| End of feedback period | October 04, 2024 |
Last Updated : April 10, 2024